- Senate passes Drug Quality and Security Act
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- FDA advisory panel to consider OTC status of NSAIDs
- ROUNDTABLE: Pharmacy’s future in sync with technology
SYDNEY — Australian drug maker QRxPharma is seeking approval for a drug that combines two painkillers in one pill, the company said Monday.
QRxPharma announced that it had filed a regulatory approval application with the Food and Drug Administration for MoxDuo IR (morphine and oxycodone). The drug is designed to release both drugs into the body immediately.
“In just four years, we have successfully moved MoxDuo IR through clinical trials and [FDA new drug application] submission by demonstrating its effectiveness and safety,” QRxPharma CEO and managing director John Holaday said. “Achievement of this milestone clearly establishes the value of this dual opioid product to patients and prescribers, as well as potential partners.